Navigation Links
Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis

LONDON, 2 July 2007: Chi-Med, the Hutchison Whampoa backed pharmaceutical and healthcare Group, today announces positive results for its Phase II proof-of-concept study for HMPL-004 in mild-to-moderate Ulcerative Colitis, a form of inflammatory bowel disease. The trial met its objective in that HMPL-004 was well tolerated and showed an equivalent drop in clinical symptom score to the comparator drug, Mesalazine, the current first-line standard of care in mild-to-moderate Ulcerative Colitis.

The Phase II proof-of-concept study, conducted by Chi-Med’s wholly-owned drug R&D subsidiary, Hutchison MediPharma Limited (“Hutchison MediPharma”), was a multi-center, randomized, double-blind, comparator study of 120 patients with mild-to-moderate Ulcerative Colitis conducted in China. The study evaluated HMPL-004 at 400mg taken three times a day, orally, compared to Mesalazine, the current first-line standard of care. The four trial endpoints were patients: clinical symptom score; overall clinical evaluation; colonoscopic score; and safety evaluation. After treatment for eight weeks, the percentage of patient’s clinical symptom score reduction for HMPL-004 was 56% versus 59% for Mesalazine in the Intent-To-Treat population. The overall remission rate (combination of complete and partial remissions) for HMPL-004 was 57% by clinical score compared to 53% for Mesalazine in the Intent-To-Treat population and 47% for HMPL-004 versus 42% for Mesalazine by colonoscopy in the Intent-To-Treat population. HMPL-004 was well tolerated in the study and the adverse event rate was half that o
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:1/23/2015)... ORLANDO, Fla. and DUBLIN , ... of the agreement with KRS Global Biotechnology, Inc. for the ... will be compounded for shipment in the United ... 503B FDA approved Outsourcing Facility capable of compounding naltrexone tablets ...
(Date:1/23/2015)... TAMPA, Fla. , Jan. 23, 2015  iMD Companies, Inc. ... plan to increase market share and grab a foothold in ... with influence, production capabilities and a presence in the sector, ... them facilitate the growth of hemp and medical marijuana, iMD ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... with the American, Botanical Council will have a dedication for ... ... The High Falls Gardens Fund,under the auspices of the Berkshire ... from the W.K. Kellogg Foundation,for a three-year program, Botanical Studies for ...
... following statement was,issued today by the law firm of Schiffrin ... that a class action lawsuit was filed in the,United States ... purchasers of securities of NeuroMetrix Inc. (Nasdaq: NURO ),("NeuroMetrix" ... inclusive (the "Class Period")., If you wish to discuss ...
... provide orthodontic treatment to disadvantaged children? Did you know ... health? Have you heard about the new biological clock ... are but a few of the thousands of pieces ... Association for Dental Research (AADR) holds its 37th Annual ...
... of research and development, scientists at SUNY Downstate Medical ... awarded a United States patent for their virtual telemicroscope. ... or other diseases in patients living in remote locations ... MD, associate professor of pathology at SUNY Downstate, and ...
... the keynote presentations, symposia, and workshops that will anchor ... Dental Research, convening April 2 at the Hilton Anatole ... 2 , Optimizing the Survival of ... Failures,Susanne Scherrer (University of Geneva, Switzerland), 3:15 p.m., Grand ...
... -- To Congress: ,Stop wasting tax dollars on ... tested too, -- Three-fifths favor stripping stats ... March 27 As this year,s,Major League Baseball ... are keeping a close eye on steroid use ...
Cached Medicine News:Health News:Oriental Medicinal Herb Garden Dedication 2Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 4Health News:Dental scientists convene in Dallas 2Health News:Dental scientists convene in Dallas 3Health News:Dental scientists convene in Dallas 4Health News:SUNY researcher issued patent for virtual telemicroscope 2Health News:Keynoters, symposia, workshops highlight dental research meeting 2Health News:Keynoters, symposia, workshops highlight dental research meeting 3Health News:Keynoters, symposia, workshops highlight dental research meeting 4Health News:Americans Guess One-Third of Professional Athletes on Performance Enhancing Drugs 2Health News:Americans Guess One-Third of Professional Athletes on Performance Enhancing Drugs 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: